scholarly journals Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Branch Retinal Vein Occlusion

2019 ◽  
Vol 2019 ◽  
pp. 1-5 ◽  
Author(s):  
Dan-dan Zhu ◽  
Xun Liu
Keyword(s):  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Roc Analysis ◽  
Control Group ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Platelet Lymphocyte Ratio ◽  
Vein Occlusion ◽  
The Mean ◽  
Age And Sex

Purpose. To evaluate the neutrophil/lymphocyte ratio (NLR) and the platelet/lymphocyte ratio(PLR) value in the development of branch retinal vein occlusion (BRVO)patients. Methods. 81 patients with BRVO and 81 age and sex-matched subjects were recruited as the control group. The BRVO diagnosis was confirmed under comprehensive ophthalmologic examinations. NLR and PLR parameters obtained from peripheral blood were recorded. Results. Both the mean NLR and PLR was significantly higher in the BRVO group compared with the control group (p < 0.001). In ROC analysis, the AUC for NLR was 0.82, and NLR of >2.48 predicted BRVO with a sensitivity of 58% and specificity of 98%. The AUC for PLR was 0.78, and PLR of >110.2 predicted BRVO with a sensitivity of 72% and specificity of 72%. Conclusion. The current study demonstrated that BRVO patients had increased NLR and PLR levels compared with control subjects. The NLR and PLR may be used as independent predictors for identifying risk for the development of BRVO.

scholarly journals Assessment of platelet-to-lymphocyte ratio in patients with retinal vein occlusion

2020 ◽  
Vol 12 ◽  
pp. 251584142097194
Author(s):  
Bengi Ece Kurtul ◽  
Ayșe İdil Çakmak ◽  
Ahmet Elbeyli ◽  
Deniz Özarslan Özcan ◽  
Sait Coșkun Özcan ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Curve Analysis ◽  
Control Group ◽  
Platelet To Lymphocyte Ratio ◽  
Age And Gender ◽  
Lymphocyte Ratio ◽  
Vein Occlusion ◽  
And Gender ◽  
Receiver Operator Characteristics ◽  
Age And Sex

Purpose: To investigate platelet-to-lymphocyte ratio (PLR) in retinal vein occlusion (RVO) patients. Methods: In this study, we retrospectively reviewed data of 32 patients with RVO (RVO group) and 32 age- and sex-matched participants without RVO (control group) between January 2017 and March 2019. The PLR was determined by dividing the platelet count by the lymphocyte count. Results: Age and gender were comparable between the groups ( p = 0.204 and p = 0.800, respectively). PLR was significantly elevated in the RVO group compared with the control group (137 (113–164) vs 101 (86–129), p = 0.001)). In the receiver operator characteristics curve analysis, the optimal cut-off value of PLR for predicting RVO was 123, with 69% sensitivity and 72% specificity. Conclusion: We report that PLR are elevated in RVO, suggesting that PLR may be a useful marker for RVO.

Association of neutrophil / lymphocyte ratio, platelet /lymphocyte ratio and brachial retinal vein occlusion

2019 ◽  
Vol 26 (10) ◽  
pp. 2154
Author(s):  
Mahmut Atum ◽  
Isa Yuvaci ◽  
Selcuk Yaylaci ◽  
Ahmed Genc ◽  
Turgay Ucak ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Platelet Lymphocyte Ratio ◽  
Vein Occlusion

scholarly journals Neutrophil/lymphocyte ratio and mean platelet volume in branch retinal vein occlusion

2016 ◽  
Vol 30 (2) ◽  
pp. 105-108 ◽  
Author(s):  
Esra Turkseven Kumral ◽  
Nursal Melda Yenerel ◽  
Nimet Yesim Ercalik ◽  
Serhat Imamoglu ◽  
Ece Turan Vural
Keyword(s):  
Retinal Vein Occlusion ◽  
Mean Platelet Volume ◽  
Branch Retinal Vein Occlusion ◽  
Platelet Volume ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Vein Occlusion

scholarly journals Efficacy of Modified Treat-and-Extend Aflibercept Regimen for Macular Edema Due to Branch Retinal Vein Occlusion: 1-Year Prospective Study

2020 ◽  
Vol 9 (8) ◽  
pp. 2360
Author(s):  
Yusuke Arai ◽  
Hidenori Takahashi ◽  
Satoru Inoda ◽  
Shinichi Sakamoto ◽  
Xue Tan ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Treat And Extend ◽  
Vein Occlusion ◽  
Corrected Visual Acuity ◽  
Intravitreal Aflibercept ◽  
Central Subfield Thickness ◽  
The Mean ◽  
First Recurrence

Purpose: To assess the efficacy and safety of a modified treat-and-extend (mTAE) regimen of aflibercept for macular edema (ME) due to branch retinal vein occlusion (BRVO). Methods: This prospective multicentre intervention study evaluated 50 eyes of 50 patients enrolled from October 2016 to September 2017. The patients received intravitreal aflibercept (IVA) injections on an mTAE regimen for a total of 12 months. The main outcome measures were best-corrected visual acuity (BCVA) and central subfield thickness (CST) at 12 months. Results: The baseline BCVA and CST were 0.33 (0.27) and 488 (171) µm (mean (standard deviation)), respectively. The BCVA and CST were significantly improved at month 12 (0.067 (0.19) LogMAR and 295 (110) µm; both p < 0.0001, paired t-test). The mean number of clinic visits and IVA injections was 6.71 (1.41) and 4.26 (0.71), respectively. The time to first recurrence from the first injection was most frequently 3 months. Conclusion: The mTAE regimen of IVA injections for ME due to BRVO effectively improved BCVA and reduced CST, and thus might be an effective therapy to reduce the number of injections and visits.

scholarly journals A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion

2018 ◽  
Vol 28 (6) ◽  
pp. 697-705 ◽  
Author(s):  
Francesco Bandello ◽  
Albert Augustin ◽  
Adnan Tufail ◽  
Richard Leaback
Keyword(s):  
Visual Acuity ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Dexamethasone Intravitreal Implant ◽  
Vein Occlusion ◽  
Corrected Visual Acuity ◽  
Increased Risk ◽  
Intravitreal Implant ◽  
The Mean ◽  
Best Corrected Visual Acuity

Purpose: Dexamethasone intravitreal implant and intravitreal ranibizumab are indicated for the treatment of macular edema secondary to retinal vein occlusion. This non-inferiority study compared dexamethasone with ranibizumab in patients with branch retinal vein occlusion. Methods: In this randomized, 12-month head-to-head comparison, subjects with branch retinal vein occlusion were assigned to dexamethasone 0.7 mg at day 1 and month 5 with the option of retreatment at month 10 or 11, or ranibizumab 0.5 mg at day 1 and monthly through month 5 with subsequent as-needed injections at month 6–month 11. The primary efficacy outcome was the mean change from baseline in best-corrected visual acuity at month 12; secondary outcomes included average change in best-corrected visual acuity, proportion of eyes with ≥10- and ≥15-letter gain/loss, change in central retinal thickness, and change in Vision Functioning Questionnaire-25 score. Results: In all, 307 of a planned 400 patients were enrolled in the study and received (mean) 2.5 dexamethasone injections (n = 154) and 8.0 ranibizumab injections (n = 153) over 12 months. The mean change from baseline in best-corrected visual acuity at month 12 was 7.4 letters for dexamethasone versus 17.4 letters for ranibizumab (least-squares mean difference (dexamethasone minus ranibizumab), −10.1 letters; 95% confidence interval, −12.9, −7.2; p = 0.0006). Conclusion: Dexamethasone and ranibizumab improved best-corrected visual acuity and anatomical outcomes; however, dexamethasone did not show non-inferiority to ranibizumab in this under-powered study. Dexamethasone was associated with an increased risk of intraocular pressure elevation and cataract progression, but a lower injection burden, compared to ranibizumab.

scholarly journals Etiology of vitreous hemorrhage in a tertiary eye care center in Nepal

1970 ◽  
Vol 2 (2) ◽  
pp. 121-126 ◽  
Author(s):  
R Sharma ◽  
SN Joshi ◽  
JK Shrestha
Keyword(s):  
Diabetic Retinopathy ◽  
Retinal Vein Occlusion ◽  
Proliferative Diabetic Retinopathy ◽  
Branch Retinal Vein Occlusion ◽  
Care Center ◽  
Retinal Vasculitis ◽  
Vitreous Hemorrhage ◽  
Cross Sectional ◽  
Vein Occlusion ◽  
The Mean

Introduction: Vitreous hemorrhage is one of the most common differential diagnoses of sudden painless decrease in vision. Objective: To find out the etiology of vitreous hemorrhage in cases of vitreous hemorrhage at a tertiary eye centre in Nepal. Materials and methods: This was a hospital-based cross-sectional study done over a period of one-and-a-half years. One hundred and one subjects with vitreous hemorrhage were evaluated in detail to establish the etiology. Statistics: The mean value and standard deviation were calculated. The data were analyzed using microsoft excel and SPSS 11.5 program. Results: A total of 122 eyes of 101 patients were evaluated. The mean age was 41.90 (± 21.50) years with a range of 2 months to 84 years. Male were 73 %. Bilateral involvement was found in 20.8 %. Proliferative diabetic retinopathy, retinal vasculitis, branch retinal vein occlusion, rhegmatogenous retinal detachment together with ocular trauma constituted the etilogoy of vitreous hemorrhage in more than 75 % of patients. Conclusion: Proliferative diabetic retinopathy, retinal vasculitis and branch retinal vein occlusion are the most common causes of vitreous hemorrhage in adults whereas in children trauma is the commonest cause. Keywords: vasculitis; vitreous hemorrhage; diabetic retinopathy; Eales disease DOI: 10.3126/nepjoph.v2i2.3718 Nep J Oph 2010;2(2) 121-126

Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion

2018 ◽  
Vol 28 (6) ◽  
pp. 690-696 ◽  
Author(s):  
Yelda Buyru Özkurt ◽  
Sezen Akkaya ◽  
Sibel Aksoy ◽  
Mert Hakan Şimşek
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Laser Treatment ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Intravitreal Ranibizumab ◽  
Micropulse Laser ◽  
Vein Occlusion ◽  
Subthreshold Micropulse Laser ◽  
The Mean

Purpose: To compare the effects of intravitreal ranibizumab injection and yellow (577 nm) subthreshold micropulse laser treatment in patients with macular edema following non-ischemic branch retinal vein occlusion. Methods: The medical records of 51 patients who underwent intravitreal ranibizumab (0.5 mg) injection or subthreshold micropulse laser for the treatment of macular edema due to branch retinal vein occlusion were retrospectively reviewed. Subthreshold micropulse laser was administered with a 10% duty cycle, 100 μm spot diameter, 200 ms exposure time. The patients received an injection or laser treatment at baseline and were, then, retreated as needed and were followed for 12 months. The mean best corrected visual acuity changes over the follow-up and the decrease in the mean central macular thickness were evaluated. Results: A total of 27 and 24 patients were assigned to intravitreal ranibizumab and subthreshold micropulse laser subgroups, respectively. The mean number of treatment was 3.81 of intravitreal ranibizumab group and 1.5 of subthreshold micropulse laser group (p < 0.05). The subgroups were similar with regard to the mean score of best corrected visual acuity at baseline, at 1, 6, and 12 months (p > 0.05). The decrease in the mean central macular thickness was significant in both intravitreal ranibizumab and subthreshold micropulse laser groups at 1, 6, and 12 months than that of values at baseline (p < 0.05). No new ocular or systemic adverse events were observed. Conclusion: Our study results showed that intravitreal ranibizumab or yellow subthreshold micropulse laser treatment for macular edema due to branch retinal vein occlusion was not found to be superior to each other for reducing macular thickness and increasing visual acuity for 1-year period. Based on these results, subthreshold micropulse laser may be a useful alternative approach in the treatment of macular edema secondary to branch retinal vein occlusion.

scholarly journals Significant elevation of aqueous endothelin-1 in central retinal vein occlusion

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0252530
Author(s):  
Hae Min Kang ◽  
Md. Hasanuzzaman ◽  
So Won Kim ◽  
Hyoung Jun Koh ◽  
Sung Chul Lee
Keyword(s):  
Retinal Vein Occlusion ◽  
Aqueous Humor ◽  
Central Retinal Vein Occlusion ◽  
Intravitreal Bevacizumab ◽  
Control Group ◽  
Endothelin 1 ◽  
Intravitreal Bevacizumab Injection ◽  
Vein Occlusion ◽  
The Mean ◽  
Central Retinal Vein

Purpose To investigate aqueous humor concentrations of endothelin-1 (ET-1) in patients with central retinal vein occlusion (CRVO) compared with patients with branch retinal vein occlusion (BRVO) and a normal control group. Methods A total 80 subjects were included in this prospective study, including 15 patients with CRVO, 20 patients with BRVO, and 45 patients who underwent cataract surgery and had no concomitant ocular disease. Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month. Results At baseline, the mean aqueous ET-1 level was 12.7±3.6 pg/mL in the CRVO group, 8.0±2.3 pg/mL in the BRVO group, and 2.0±0.9 pg/mL in the control group (P<0.001). After IVB, the mean aqueous level of ET-1 was 3.4±1.9 pg/mL (0.5–6.9 pg/mL) in the CRVO group and 1.8±1.0 pg/mL (0.3–3.2 pg/mL) in the BRVO group (P = 0.008). The mean aqueous ET-1 level was significantly reduced in both the patients with CRVO and those with BRVO (P<0.001). Conclusion The mean aqueous humor ET-1 level was significant higher in the patients with CRVO than those with BRVO and in the control group. After IVB, the mean level was significantly reduced in both the patients with CRVO and those with BRVO.

Abstract WP92: Neutrophil-lymphocyte Ratio in Cerebral Aneurysm

Stroke ◽  
2016 ◽  
Vol 47 (suppl_1) ◽  
Author(s):  
Kee Ook Lee ◽  
Kyung-Yul Lee ◽  
Jae-Youn Kim ◽  
Cheol-Young Lee ◽  
Sang-Jun Na ◽  
...  
Keyword(s):  
Cerebral Aneurysm ◽  
Control Group ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Patients With Cancer ◽  
The Mean ◽  
Artery Disease ◽  
Wbc Count ◽  
And Control

Introduction: Blood neutrophil/lymphocyte ratio (NLR) is a simple marker of subclinical inflammation that can be easily obtained. The NLR has recently emerged as a prognostic marker in patients with cancer and coronary artery disease. However, little is known about the role of NLR in patients with intracranial aneurysm (IA). Hypothesis: The purpose of this study was to determine the clinical significance of NLR in patients with IA. Methods: The study group consisted of patients with IA who had been admitted to the neurology department from January 2008 to December 2014. A total of 362 patients including 176 patients with unruptured IA, 186 patient with ruptured IA were enrolled in this study. The control group consisted of 178 age, sex-matched healthy adults who had not harbor IA by CTA, MRA, DSA. The baseline NLR was calculated as the ratio of neutrophil count to lymphocyte count. WBC count>12.000 cells per μL or <4.000 cells per μL and high body temperature>38 ° are excluded from the study. Results: The Mean NLR was significantly higher among persons with cerebral aneurysm compared with controls (P < 0.001). The level of NLR in ruptured IA group were found higher compared to unruptured IA and control group (7.0 ± 6.6 vs 2.5 ± 1.5 vs 1.6 ± 0.5, P < 0.001). Other comorbid conditions were balanced between these three groups. Conclusions: Higher NLR is associated with cerebral aneurysm. Unlike many other inflammatory markers and bioassays, NLR are inexpensive and readily available biomarkers that may be useful for risk stratification in patients with cerebral aneurysm.

Sign in / Sign up

Export Citation Format

Share Document